1/ It is no surprise that Semaglutide is the bell of the pharmacotherapy ball. Let's review some key takeaways from the STEP trials to understand why SEMA 2.4 mg is so exciting.
*credit to Dr. Wadden. #OW2021
STEP 3
2/ Intervention: Intensive Behavioral Therapy + Low Calorie Diet +/- SEMA 2.4 mg #OW2021
3/
Control arm: IBT + LCD lost ~6% BW.
vs.
Experimental arm: IBT/LCD/SEMA 2.4 lost 16% BW. #OW2021
4/ Weight loss is comparable with SEMA 2.4 mg regardless of whether patients receives intensive behavioral therapy/LCD or not.
--
‼️ The implication is that SEMA 2.4 mg is doing the heavy lifting in normalizing physiology to promote weight loss. #OW2021
5/ So, how does SEMA 2.4 mg compare to other FDA-approved treatments for obesity? #OW2021
6/ Major Lessons from the STEP trial:
❗️ SEMA 2.4 mg promotes clinically significant placebo-subtracted weight loss
‼️ Many CVD risk factors improved, ongoing CVOT (SELECT trial)
❗️‼️ <5% discontinuation due to GI side effects, rare pancreatitis and cholelithiasis #OW2021
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.